Get Cash Back and $0 Commissions
+ The Power of TradeStation

Zoetis (ZTS) Stock Declines Amid Concerns Over Arthritis Drugs Impacting Pets Hagens Berman

Globe Newswire 16-May-2024 12:43 PM

SAN FRANCISCO, May 16, 2024 (GLOBE NEWSWIRE) -- Hagens Berman is urging investors who suffered substantial losses in Zoetis Inc. (NYSE:ZTS) to promptly report their losses here. Additionally, individuals with relevant knowledge who may assist in the investigation are encouraged to contact the firm's attorneys.

Contact the Firm Now: Phone: 844-916-0895

Zoetis Inc. (ZTS) Investigation:

The investigation centers around Zoetis' arthritis drugs, specifically Librela™ and Solensia™, which are designed to alleviate painful osteoarthritis in dogs and cats, respectively.

Historically, these products have been significant revenue drivers for Zoetis' companion animal division, with the company projecting peak sales of over $1 billion for its osteoarthritis pain franchise.

However, a Wall Street Journal article published on Apr. 12, 2024 titled "What Killed Their Pets? Owners Blame Meds, but Vets Aren't Sure" has cast doubt on Zoetis' prospects. Pet owners have attributed illnesses and, in some cases, fatalities to the company's drugs. Health regulators in the U.S. and Europe have received thousands of reports of side effects and are currently conducting reviews. Wall Street analysts have also raised questions about the complaints from pet owners.

This news sent the price of Zoetis shares down $12.75 (7.8%) on Apr. 12, 2024.

"We are investigating whether Zoetis may have misrepresented the safety of its pet arthritis drugs," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Zoetis and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now.

If you'd like more information and answers to frequently asked questions about the Zoetis investigation, read more.

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at Follow the firm for updates and news at @ClassActionLaw.

Reed Kathrein, 844-916-0895

Image for Press Release 1900175
Image for Press Release 1900175

Primary Logo